CA3134816A1 - Compositions and methods for treating ocular disease - Google Patents
Compositions and methods for treating ocular disease Download PDFInfo
- Publication number
- CA3134816A1 CA3134816A1 CA3134816A CA3134816A CA3134816A1 CA 3134816 A1 CA3134816 A1 CA 3134816A1 CA 3134816 A CA3134816 A CA 3134816A CA 3134816 A CA3134816 A CA 3134816A CA 3134816 A1 CA3134816 A1 CA 3134816A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- peptide
- unit dose
- salt
- abu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962824017P | 2019-03-26 | 2019-03-26 | |
| US62/824,017 | 2019-03-26 | ||
| PCT/US2020/024972 WO2020198481A1 (en) | 2019-03-26 | 2020-03-26 | Compositions and methods for treating ocular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3134816A1 true CA3134816A1 (en) | 2020-10-01 |
Family
ID=72609544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3134816A Pending CA3134816A1 (en) | 2019-03-26 | 2020-03-26 | Compositions and methods for treating ocular disease |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12540171B2 (https=) |
| EP (1) | EP3946418A4 (https=) |
| JP (1) | JP7650074B2 (https=) |
| KR (1) | KR20210146352A (https=) |
| CN (1) | CN113710264A (https=) |
| AU (1) | AU2020248438A1 (https=) |
| CA (1) | CA3134816A1 (https=) |
| EA (1) | EA202192607A1 (https=) |
| IL (1) | IL286625A (https=) |
| MX (1) | MX2021011727A (https=) |
| WO (1) | WO2020198481A1 (https=) |
| ZA (1) | ZA202107235B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| CN117126233A (zh) * | 2022-05-20 | 2023-11-28 | 杭州禾泰健宇生物科技有限公司 | 一种类肽化合物及其应用 |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2015781A4 (en) * | 2005-09-12 | 2009-12-23 | Univ Johns Hopkins | COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF |
| EP2649095B1 (en) * | 2010-12-10 | 2021-10-06 | Aleksander S. Popel | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| JP6470740B2 (ja) * | 2013-06-07 | 2019-02-13 | ザ ジョンズ ホプキンス ユニバーシティ | 血管新生およびリンパ管新生依存性疾患の処置のための生体模倣ペプチドおよび生分解性送達プラットフォーム |
| CN108883150A (zh) | 2015-11-19 | 2018-11-23 | 阿斯克雷佩西治疗公司 | 具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂 |
| MX2019003895A (es) * | 2016-10-04 | 2019-10-07 | Asclepix Therapeutics Inc | Compuestos y metodos para activar la señalizacion tie2. |
| US20200179285A1 (en) * | 2017-05-08 | 2020-06-11 | The Johns Hopkins University | Biodegradable microparticles for sustained delivery of anti-angiogenic peptide |
| EP3661536A4 (en) * | 2017-08-03 | 2021-07-21 | Asclepix Therapeutics, Inc. | PROCESS FOR IDENTIFICATION AND MANUFACTURING OF PHARMACEUTICAL INGREDIENTS FOR ACTIVATING A TIE2 RECEPTOR |
-
2020
- 2020-03-26 CN CN202080030026.4A patent/CN113710264A/zh active Pending
- 2020-03-26 KR KR1020217034683A patent/KR20210146352A/ko active Pending
- 2020-03-26 EP EP20776493.7A patent/EP3946418A4/en active Pending
- 2020-03-26 US US17/442,682 patent/US12540171B2/en active Active
- 2020-03-26 WO PCT/US2020/024972 patent/WO2020198481A1/en not_active Ceased
- 2020-03-26 AU AU2020248438A patent/AU2020248438A1/en active Pending
- 2020-03-26 JP JP2021557369A patent/JP7650074B2/ja active Active
- 2020-03-26 EA EA202192607A patent/EA202192607A1/ru unknown
- 2020-03-26 MX MX2021011727A patent/MX2021011727A/es unknown
- 2020-03-26 CA CA3134816A patent/CA3134816A1/en active Pending
-
2021
- 2021-09-23 IL IL286625A patent/IL286625A/en unknown
- 2021-09-27 ZA ZA2021/07235A patent/ZA202107235B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210146352A (ko) | 2021-12-03 |
| AU2020248438A1 (en) | 2021-10-28 |
| ZA202107235B (en) | 2023-10-25 |
| WO2020198481A1 (en) | 2020-10-01 |
| EP3946418A4 (en) | 2023-02-22 |
| US12540171B2 (en) | 2026-02-03 |
| JP7650074B2 (ja) | 2025-03-24 |
| EA202192607A1 (ru) | 2022-03-03 |
| US20230054032A1 (en) | 2023-02-23 |
| CN113710264A (zh) | 2021-11-26 |
| IL286625A (en) | 2021-12-01 |
| MX2021011727A (es) | 2022-01-24 |
| JP2022527276A (ja) | 2022-06-01 |
| EP3946418A1 (en) | 2022-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11738064B2 (en) | Pharmaceutical composition for preventing and treating eye diseases, containing as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused | |
| CN109715189B (zh) | 靶向VE-PTP(HPTP-β)的人源化单克隆抗体 | |
| ES3041647T3 (en) | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders | |
| JP2016522250A (ja) | 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用 | |
| CN105377891A (zh) | Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用 | |
| KR20120130752A (ko) | 혈관신생-관련된 안질환의 치료를 위한 조성물 및 방법 | |
| US12540171B2 (en) | Compositions and methods for treating ocular disease | |
| ES2886542T3 (es) | Uso de sirolimus para tratar la degeneración macular asociada con la edad exudativa con edema persistente | |
| ES2820710T3 (es) | Péptidos para inhibir la angiogénesis | |
| AU2020414152B2 (en) | Application of fusion protein in treating age-related macular degeneration | |
| US20160129080A1 (en) | Treatment of polypoidal chroidal vasculopathy | |
| KR20220062279A (ko) | 안질환의 치료 방법 | |
| TW201904610A (zh) | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 | |
| EP4251204A1 (en) | Vegf antagonist for use in methods for treating ocular diseases | |
| KR20220051791A (ko) | Fas 신호전달 억제용 펩타이드를 포함하는 황반변성 예방 또는 치료용 조성물 | |
| WO2026036282A1 (en) | Multispecific fusion proteins targeting angiogenic factors | |
| EP4429693B1 (en) | Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion | |
| WO2025054768A1 (en) | Multispecific fusion proteins targeting angiogenic and inflammatory factors | |
| HK40115628B (en) | Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion | |
| HK40115628A (en) | Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion | |
| IL324669A (en) | Annexin A5 protein as a combination therapy with an anti-VEGF agent for use in the treatment of macular edema or retinal vein occlusion | |
| KR20260019535A (ko) | 보체 항체-약물 접합체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240325 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250724 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250724 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251007 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251127 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260206 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260211 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260211 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20260315 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260315 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260315 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260315 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260415 |